At the premiere conference for radiation oncology, Provision will unveil plans and a progress report for expansion and release results of a patient survey that confirms proton therapy’s benefit for cancer patients.
The annual meeting for the American Society for Radiation Oncology, or ASTRO, begins Sunday in Boston. The conference attracts more than 10,000 attendees from the radiation oncology community—from physicians to instrument makers. Provision Healthcare is an event sponsor and be at the trade show – Booth #12091.
In addition to research presentations and networking opportunities, the conference offers a platform for companies like Provision to share important business developments with the rest of the industry.
The official releases will come out over the next few days. But here are a few teasers:
New center planned for Orlando
Provision Healthcare and Hamlin Retail Partners West, an affiliate of Boyd Development Corporation and Schrimsher Properties, announced a joint venture to develop and operate a proton therapy center as part of a medical campus in Hamlin, an 850-acre mixed-use town center development in southwest Orange County.
“The Provision Proton Center in Orlando will be our third center in the southeastern U.S., as Provision Healthcare continues to pursue our mission to make advanced cancer care and proton therapy more accessible by developing joint venture proton centers and cancer centers in the U.S., China, and around the world”, said Dr. Terry Douglass, Chairman and CEO of Provision Healthcare.
Construction proceeds at Scott Hamilton Proton Therapy Center
The two-story building includes three treatment rooms along with clinical and administrative office space. It is located in a growing and developing healthcare hub in Franklin, Tennessee. The $99.6 million project is scheduled to treat the first patient in mid-2018. The Center will utilize Provision Healthcare’s ProNova SC360 proton system. The first ProNova SC360 system plans to treat first patient at the Provision Center for Proton Therapy in Knoxville, Tennessee later this year.
Prostate cancer patients tout proton therapy in national survey
A national survey released today reported that men treated for prostate cancer who received proton therapy reported significantly better quality of life than those who selected other therapy options. The survey results, announced from Provision Healthcare, profiled 755 men, ages 50-75, who were surveyed at least 12 months after treatment.
More than 70 percent of those who received proton therapy for their cancer said they experienced good quality of life after treatment compared with 42 percent of patients receiving conventional radiation therapy, 46 percent of patients receiving brachytherapy, and 29 percent of patients who underwent surgery.